



Mitsubishi Gas Chemical Company, Inc.

July 29, 2011

### **Regarding the ITC Proceeding concerning Coenzyme Q10**

MITSUBISHI GAS CHEMICAL COMPANY, INC. (Head Office: Chiyoda-ku, Tokyo, President, Representative Director: Kazuo Sakai) (hereinafter called "MGC") received a notice dated July 14th from the U.S. International Trade Commission (ITC) that the ITC will investigate the allegations by Kaneka Corporation (Head Office: Kita-ku, Osaka, President: Kimikazu Sugawara) (hereinafter called "Kaneka") that substantially all Coenzyme Q10 imported into the United States infringes Kaneka's recently issued U.S. Patent No.7910340 on a method for making that product.

MGC is confident that the ITC will quickly find that the process used by MGC does not infringe any valid claim of the patent.

MGC has been making its Coenzyme Q10 product by its own process and selling Coenzyme Q10 in the United States for over 20 years, long before Kaneka applied for its patent. We are confident that we do not infringe any valid claim of the U.S. patent owned by Kaneka. We have retained leading U.S. and Japanese legal counsel, who will vigorously defend MGC in obtaining favorable results quickly.

MGC expects that there will be no effect of the ITC proceeding on our business of Coenzyme Q10. To our customers, we appreciate your business with us and we are confident that you will continue using our Coenzyme Q10 without concerns.

Regarding any questions on this matter, please contact:

Corporate Communications Division

TEL: 03-3283-5041